LOI Deadline
Sponsor Deadline
Posted: 3/27/2024

Congressionally Directed Medical Research Programs -- Ovarian Cancer Research Program -- Clinical Trial Translational Endpoints Research Award

The FY24 OCRP Clinical Trial Translational Endpoints Research Award intends to support correlation of clinical trial-related data (e.g., biosample analysis, imaging, or epidemiological data) with clinical outcomes or responses to therapies. Correlative studies may be associated with a past, ongoing, or future clinical trial in order to associate various factors (genetic, biochemical, environmental and others) with initiation, progression, metastasis, recurrence, prognosis, diagnosis or effect of intervention on ovarian cancer outcomes. The translational research should address high-impact or unmet needs in ovarian cancer. The proposed research may be hypothesis testing or may be designed to generate new hypotheses to be tested in follow-up clinical research. The award may not be used to directly support a clinical trial.

Examples of studies appropriate for submission to the FY24 OCRP Clinical Trial Translational Endpoints Research Award include, but are not limited to:
• Using patient-based resources to link biosamples to rigorous molecular data.
• Collecting and analyzing biospecimens as a companion to an anticipated/ongoing clinical trial.
• Clinical biomarker validation.
• Development of clinical endpoints for future clinical trials.
• Continuation of clinical follow-up of patients currently/previously enrolled in an open/ongoing or completed clinical trial.


• Pre-Application (Letter of Intent) Submission Deadline: June 3, 2024
• Application Submission Deadline: August 6, 2024

Areas of Interest

To meet the intent of the funding opportunity, applications for the FY24 OCRP Clinical Trial Translational Endpoints Research Award must address a critical component of at least one of the Areas of Emphasis listed below:
• Understand the basic biology and etiology of ovarian cancer initiation, progression, metastasis, recurrence, genetics, proteogenomic and other critical events.
• Develop novel therapeutic strategies for treatment.
• Investigate innovative approaches for ovarian cancer prevention.
• Identify and develop new strategies for screening, early-stage detection, accurate diagnosis, and prognosis.
• Identify and implement strategies to improve the survivorship and quality of life.
• Address health disparities.
• Improve precision medicine.

Eligibility Requirements

The Principal Investigator (PI) must be at or above the level of Assistant Professor (or equivalent) to be eligible to submit an application.
An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by or affiliated with an eligible organization.

Amount Description

The anticipated direct costs budgeted for the entire period of performance for an FY24 OCRP Clinical Trial Translational Endpoints Research] Award should not exceed $1M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

LOI Deadline: